News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer AG (BAYN.DE)'s Stivarga Approved for Further Indication in Japan



8/21/2013 7:30:56 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Germany's largest drugmaker Bayer said it received regulatory approval in Japan for the marketing of cancer treatment Stivarga for patients with gastrointestinal stromal tumours who have progressed after prior systemic cancer therapy. Stivarga is already approved in several countries, including the United States and Japan, for the treatment of patients with metastatic colorectal cancer (mCRC), Bayer said on Tuesday.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES